SANBIO COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 430 JPY | -0.23% |
|
+1.65% | -38.75% |
| Mar. 19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
| Mar. 19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
Presenter SpeechKeita Mori (Executives)Good afternoon. This is Keita Mori from SanBio. Thank you for all t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Calendar
2024-06-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
431
JPY
Average target price
800
JPY
Spread / Average Target
+85.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.75% | 184M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- 4592 Stock
- News SanBio Company Limited
- Transcript : SanBio Company Limited, Q2 2022 Earnings Call, Sep 16, 2021
